VVY Stock Price, News & Analysis

Vivoryon Therapeutics (Euronext: VVY) will publish its Q3 2025 financial results and provide an operational update on December 4, 2025. The company will host a public conference call and live webcast at 3:00 pm CET / 9:00 am EST to discuss results and corporate developments.

Investors can access the live audio webcast on the company's investor site and join the call by pre-registering for phone dial-in details. Attendees are advised to dial in 15 minutes before the scheduled start to avoid delays.

Vivoryon Therapeutics (Euronext: VVY) presented Phase 2 kidney function and biomarker data on November 6, 2025 at ASN Kidney Week 2025. A late-breaking poster titled “Correlation of eGFR and pE-CCL2 in Older Adult Patients Treated with Varoglutamstat: Data from VIVIAD, a Phase 2B Randomized Clinical Trial” reported that a decrease in pE-CCL2 at week 48 correlated significantly with a positive (improved) eGFR slope on an individual-patient level. Prior VIVIAD Phase 2b results also linked pE-CCL2 reduction with eGFR improvement across dose groups and in participants with and without diabetes. Vivoryon said it plans a dedicated Phase 2b in advanced diabetic kidney disease (DKD stage 3b/4), with initiation subject to additional funding or partnership.

Vivoryon Therapeutics (Euronext: VVY) announced management will participate in multiple medical and investor conferences in November 2025.

Key events: ASN Kidney Week 2025 (Houston, Nov 5–9) where Vivoryon presents a late-breaking poster on eGFR and pE-CCL2 correlation from the Phase 2b VIVIAD trial (TH-PO1206) on Nov 6, 10:00 am–12:00 pm CST; 1x1 meetings around Jefferies Global Healthcare Conference (London, Nov 18–20); and Deutsches Eigenkapitalforum (Frankfurt, Nov 24–26).

Attending speakers include Michael Schaeffer, PhD, Frank Weber, MD, and Julia Neugebauer, PhD. Investor meeting requests via IR@vivoryon.com.

Vivoryon Therapeutics (Euronext: VVY) completed a private placement on October 6, 2025, raising EUR 5.1 million by issuing 3,380,500 new ordinary shares at EUR 1.50 per share.

The placement equals 12.9% dilution of existing share capital, raises shares outstanding to 29,614,337, and increases share capital from EUR 262,338.37 to EUR 296,143.37.

Proceeds will fund near-term development of lead candidate varoglutamstat in diabetic kidney disease, support partnership negotiations, and provide a cash runway well into Q3 2026. New shares are expected to trade on Euronext Amsterdam on October 7, 2025 with delivery around October 9, 2025.

Vivoryon Therapeutics N.V. (VVY) reported H1 2025 financial results and significant progress in their kidney disease program. Key highlights include compelling kidney function data from two Phase 2 studies (VIVIAD and VIVA-MIND), showing varoglutamstat's ability to improve eGFR values. The company secured a new U.S. patent for varoglutamstat extending protection through 2044.

Financial results show a reduced net loss of EUR 5.5M compared to EUR 13.6M in H1 2024, with R&D expenses decreasing to EUR 2.8M from EUR 10.3M. Cash position stands at EUR 4.8M, expected to fund operations into January 2026. The company entered a EUR 15M Standby Equity Purchase Agreement with Yorkville Advisors and is actively seeking additional funding for planned Phase 2b DKD studies.

Pre-clinical data revealed synergistic effects when combining varoglutamstat with SGLT-2 inhibitors, showing promising results in inflammation, fibrosis, and kidney function markers.

Vivoryon Therapeutics N.V. (Euronext Amsterdam: VVY), a clinical stage company focused on developing small molecule medicines for inflammatory and fibrotic disorders, particularly kidney diseases, has scheduled its H1 2025 financial results announcement for September 4, 2025.

The company will host a conference call and webcast at 3:00 pm CEST / 9:00 am EDT. The financial report will be accessible on Vivoryon's website, and participants can join via phone by pre-registering through the provided link or attend via live audio webcast.

Vivoryon Therapeutics N.V. (Euronext Amsterdam: VVY), a clinical stage company focused on developing small molecule medicines for inflammatory and fibrotic disorders, particularly kidney diseases, has announced its upcoming participation in two virtual investor conferences.

Management will present at the mwb online Health Care Conference on July 1, 2025, at 12:00 pm CEST, and the H.C. Wainwright 4th Annual Kidney Virtual Conference on July 14, 2025, at 3:00 pm CEST / 9:00 am EDT. CEO Frank Weber and COO Julia Neugebauer will represent the company at both events.

Vivoryon Therapeutics N.V. (Euronext Amsterdam: VVY), a clinical stage company focused on developing small molecule medicines for inflammatory and fibrotic disorders, particularly diabetic kidney disease, held its 2025 Annual General Meeting (AGM) on June 24, 2025.

Shareholders approved all agenda items, including the appointment of Dr. Julia Neugebauer (COO since May 2025) as executive director. The meeting also confirmed the re-appointment of executive directors Dr. Frank Weber and Anne Doering, along with non-executive directors Dr. Erich Platzer, Charlotte Lohmann, Dr. Claudia Riedl, and Dr. Samir Shah.

Vivoryon Therapeutics reported Q1 2025 financial results and operational progress, focusing on advancing varoglutamstat for kidney disease treatment. Key highlights include encouraging preclinical data showing synergistic effects when combining varoglutamstat with SGLT-2 inhibitors, and a new U.S. patent extending exclusivity through 2044. The company's net loss decreased to EUR 2.5M from EUR 9.3M year-over-year, with cash position at EUR 7.0M as of March 31, 2025. R&D expenses decreased to EUR 1.2M from EUR 7.4M due to clinical trial completions. Vivoryon secured a EUR 15M Standby Equity Purchase Agreement with Yorkville Advisors and expects current funding to last until January 2026. The company plans to initiate a Phase 2b study in diabetic kidney disease, subject to additional funding or partnership.